Results 11 to 20 of about 5,403 (175)
Immunostimulatory effects of radioimmunotherapy [PDF]
Journal for ImmunoTherapy of Cancer, 2022 Radiation therapy (RT) is known for its ability to kill cancer cells in an immunogenic manner. Recent preclinical data demonstrate that targeted alpha-particle therapy shares with RT the capacity to elicit immunostimulatory effects, standing out as a promising strategy to circumvent immune checkpoint inhibitor resistance in immunologically ‘cold ...
Constanzo, Julie +2 more
openaire +3 more sources
Cell Death Discovery, 2022 Radiation resistance and unsatisfactory efficacy of radioimmunotherapy are important barriers to non-small cell lung cancer (NSCLC) treatment. The impacts of anlotinib on radiation and tumor immune microenvironment (TIME) in NSCLC remain to be resolved ...
Dong Han +5 more
doaj +1 more source
Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor
Frontiers in Oncology, 2021 Desmoplastic small round cell tumor (DRSCT) is a highly aggressive primitive sarcoma that primarily affects adolescent and young adult males. The 5-year survival rate is 15-30% and few curative treatment options exist.
Madelyn Espinosa-Cotton +1 more
doaj +1 more source
Frontiers in Oncology, 2013 Radioimmunotherapy has demonstrated efficacy with acceptable toxicity leading to approval in non-Hodgkin’s lymphoma, but has been slower to develop for the treatment of advanced solid tumors.
Scott T Tagawa +11 more
doaj +1 more source
Fate of 177Lu-CHX-A”-DTPA-Rituximab: In vitro Evaluation in Raji Cell Line
Journal of Radiation and Cancer Research, 2023 Context: Radioimmunotherapy is an emerging treatment modality for various types of cancers. While immunotherapy using monoclonal antibodies has shown promising results, particularly in hematological malignancies, a significant number of patients develop ...
Saloni Arun Samant +2 more
doaj +1 more source
Seminars in Radiation Oncology, 2000 Radioimmunotherapy (RIT) is a promising new therapy for the treatment of a variety of malignancies. General principles of RIT are discussed, including important considerations in the selection of monoclonal antibodies (MAb) and radionuclides for RIT.
S J, Knox, R F, Meredith
openaire +2 more sources
Pretargeted radioimmunotherapy
International Journal of Radiation Oncology*Biology*Physics, 2006 This brief review covers the concept of pretargeted radioimmunotherapy and summarize the results obtained in preclinical animal models and initial phase I clinical trials. Reagents studied have been a bifunctional antibody prepared by crosslinking Fab' fragments from two antibodies with different specificity, one binding the target antigen expressed on
Ruby F, Meredith, Donald J, Buchsbaum
openaire +4 more sources
Experimental Hematology & Oncology, 2012 Background Repeated administration of antibody-based therapies such as radioimmunotherapy depends on preserved antigen expression in tumor lesions. The purpose of this study was to evaluate whether the antigen expression in metastases observed after ...
Elgström Erika +4 more
doaj +1 more source
Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
PLoS ONE, 2009 BackgroundTo date, inefficient delivery of therapeutic doses of radionuclides to solid tumors limits the clinical utility of radioimmunotherapy. We aim to test the therapeutic utility of Yttrium-90 ((90)Y)-radio-conjugates of a monoclonal antibody, which
Fares Al-Ejeh +2 more
doaj +1 more source
Current concepts of 131I therapy in oncology: Indications, methods and follow up [PDF]
Archive of Oncology, 2006 Radioiodine in various forms (as sodium iodide and as the iodinated compounds MIBG, LIPIODOL, et al.) has been used as a therapeutic agent in oncology. Differentiated thyroid carcinoma (DTC) has been successfully treated by 131I therapy.
Mihailović Jasna
doaj +1 more source